These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28885488)

  • 1. Complement (C1q) Binding De Novo Donor-Specific Antibodies and Cardiac-Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
    Das BB; Lacelle C; Zhang S; Gao A; Fixler D
    Transplantation; 2018 Mar; 102(3):502-509. PubMed ID: 28885488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
    Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation.
    Farrero Torres M; Pando MJ; Luo C; Luikart H; Valantine H; Khush K
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28940521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
    Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
    J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
    Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
    Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients.
    Hayde N; Solomon S; Caglar E; Ge J; Qama E; Colovai A
    Pediatr Transplant; 2021 Mar; 25(2):e13885. PubMed ID: 33131194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between post-transplant donor-specific antibodies and recipient outcomes in simultaneous liver-kidney transplant recipients: single-center, cohort study.
    Yazawa M; Cseprekal O; Helmick RA; Talwar M; Balaraman V; Podila PSB; Agbim UA; Maliakkal B; Fossey S; Satapathy SK; Sumida K; Kovesdy CP; Nair S; Eason JD; Molnar MZ
    Transpl Int; 2020 Feb; 33(2):202-215. PubMed ID: 31647143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.
    Clerkin KJ; Farr MA; Restaino SW; Zorn E; Latif F; Vasilescu ER; Marboe CC; Colombo PC; Mancini DM
    J Heart Lung Transplant; 2017 May; 36(5):540-545. PubMed ID: 27916323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Pretransplant Complement-fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation.
    Thammanichanond D; Wiwattanathum P; Mongkolsuk T; Kantachuvesiri S; Worawichawong S; Vallipakorn SA; Kitpoka P
    Transplant Proc; 2016 Apr; 48(3):756-60. PubMed ID: 27234729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Complement-binding Donor-specific Antibodies, Not IgG-antibody Strength Nor C4d Status, at Antibody-mediated Rejection Diagnosis Is an Independent Predictor of Kidney Graft Failure.
    Malheiro J; Santos S; Tafulo S; Dias L; Martins S; Fonseca I; Almeida M; Pedroso S; Beirão I; Castro-Henriques A; Cabrita A
    Transplantation; 2018 Nov; 102(11):1943-1954. PubMed ID: 29757900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
    Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
    Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients.
    Zeevi A; Lunz J; Feingold B; Shullo M; Bermudez C; Teuteberg J; Webber S
    J Heart Lung Transplant; 2013 Jan; 32(1):98-105. PubMed ID: 23142561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure.
    Cazarote HB; Shimakura S; Valdameri JS; Contieri FLC; von Glehn CQC; Aita CM; Susin MF; Sotomaior VS; Glehn-Ponsirenas R
    Transpl Immunol; 2018 Aug; 49():33-38. PubMed ID: 29596992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients.
    Fichtner A; Süsal C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Opelz G; Tönshoff B
    Pediatr Nephrol; 2016 Jul; 31(7):1157-66. PubMed ID: 26928311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.
    Kuppachi S; Holanda D; Gallegos S; Field EH
    Clin Transpl; 2016; 32():127-134. PubMed ID: 28564530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss.
    Courant M; Visentin J; Linares G; Dubois V; Lepreux S; Guidicelli G; Thaunat O; Merville P; Couzi L; Taupin JL
    Nephrol Dial Transplant; 2018 Oct; 33(10):1853-1863. PubMed ID: 29672702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of C1q-binding anti-HLA antibodies as a predictor of lung allograft outcome.
    Brugière O; Roux A; Le Pavec J; Sroussi D; Parquin F; Pradère P; Dupin C; Bunel V; Mourin G; Jebrak G; Dauriat G; Castier Y; Mordant P; Lortat-Jacob B; Jean-Baptiste S; Mal H; Suberbielle C; Gautreau C; Caillat-Zucman S; Cazes A; Thabut G; Taupin JL
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29976654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of C1q Binding Status With De Novo HLA Antibody Clinical Features and Allograft Function in Kidney Transplantation Patients During Eight Years of Dynamic Follow-up.
    Wei X; Yuan X; Sun M; Pan Z; Hu L; Wang L; He J; Hou J
    Transplant Proc; 2016; 48(6):1944-54. PubMed ID: 27569927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.